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Abstract
Background: In contemporary medical research, randomised controlled trials are seen as the
gold standard for establishing treatment effects where it is ethical and practical to conduct them.
In palliative care such trials are often impractical, unethical, or extremely difficult, with multiple
methodological problems. We review the utility of Cochrane reviews in informing palliative care
practice.
Methods: Published reviews in palliative care registered with the Cochrane Pain, Palliative and
Supportive Care Group as of December 2007 were obtained from the Cochrane Database of
Systematic Reviews, issue 1, 2008. We reviewed the quality and quantity of primary studies
available for each review, assessed the quality of the review process, and judged the strength of the
evidence presented. There was no prior intention to perform any statistical analyses.
Results: 25 published systematic reviews were identified. Numbers of included trials ranged from
none to 54. Within each review, included trials were heterogeneous with respect to patients,
interventions, and outcomes, and the number of patients contributing to any single analysis was
generally much lower than the total included in the review. A variety of tools were used to assess
trial quality; seven reviews did not use this information to exclude low quality studies, weight
analyses, or perform sensitivity analysis for effect of low quality. Authors indicated that there were
frequently major problems with the primary studies, individually or in aggregate. Our judgment was
that the reviewing process was generally good in these reviews, and that conclusions were limited
by the number, size, quality and validity of the primary studies.
We judged the evidence about 23 of the 25 interventions to be weak. Two reviews had stronger
evidence, but with limitations due to methodological heterogeneity or definition of outcomes. No
review provided strong evidence of no effect.
Conclusion: Cochrane reviews in palliative care are well performed, but fail to provide good
evidence for clinical practice because the primary studies are few in number, small, clinically
heterogeneous, and of poor quality and external validity. They are useful in highlighting the
weakness of the evidence base and problems in performing trials in palliative care.
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In contemporary medical research, randomised control-
led trials are seen as the gold standard for establishing
treatment effects where it is ethical and practical to con-
duct them. In palliative care, randomised controlled trials
may be impractical, unethical, or extremely difficult, with
multiple methodological problems. The fact and nature of
these issues with palliative care trials has been frequently
commented upon [1-3]. Frequently encountered prob-
lems include recruitment and attrition, insufficient num-
bers of patients for any comparison, clinical heterogeneity
between patients (condition palliated, comorbidity), het-
erogeneity in treatments (intervention, dose, duration),
different outcomes reported, and use of non-standard
scales. A palliative care Outcomes Working Group has
recently made recommendations on outcomes they con-
sider to be important in this context and how they might
be sought in clinical trials [4].
Trials that have been done in palliative care are often
small, diverse in nature and outcomes, and with high
attrition rates, making meta-analysis, and even qualitative
systematic review, impractical, unsatisfactory, or both.
Moreover, some aspects of palliative care are difficult to
capture, given the nature of palliative care as a person-cen-
tred approach, in which individual packages of care are
often the norm [5].
With this background, the value of systematic reviews of
randomized trials in palliative care might be questioned.
One side of the argument would be that without a suffi-
ciency of trials satisfying criteria of quality, validity, and
size [6] systematic reviews are worthless. Another would
see systematic reviews as a necessary first step to obtaining
more evidence; despite their limitations, they at least tell
us what we don't know, and may indicate how to
improve.
This review set out to examine a subset of Cochrane
reviews published under the auspices of the Pain, Pallia-
tive, and Supportive Care Review Group, to ascertain the
number of successfully completed palliative care system-
atic reviews from this source over the last nine years, to
assess their quality and the strength of the evidence pre-
sented to guide clinical practice.
Methods
A list of published reviews relating to palliative care and
registered with the Cochrane Pain, Palliative and Support-
ive Care Group was obtained from the Review Group
Coordinator as of December 2007. Copies of each review
were obtained from the Cochrane Database of Systematic
Reviews using the most recent upload, issue 1, 2008.
The following information was extracted from each
review:
• Number of studies included
• Number of patients included
• Condition palliated
• Intervention
• Trial design (randomized, observational)
• Measures of quality and/or validity used
• Whether exclusions due to poor quality were made, or a
sensitivity analysis presented
• Whether a pooled analysis was done
• Original authors' conclusion on efficacy
• Original authors' conclusion on strength of evidence
• Original authors' implications for future research.
Two reviewers (GH, SD) independently carried out data
extraction, using a standard form, and assessed the quality
of each review using the Oxman & Guyatt Index of Scien-
tific Quality [7]. To determine the strength of the evidence
presented, for each review we assessed the quality of the
included studies, based on randomization and blinding
since these characteristics are known to affect potential
bias [8], and the number of patients available for any
analysis, because small numbers are prone to random
error [9,10]. Any discrepancies were resolved by consen-
sus.
There was no prior intention to perform any statistical
analyses. What was intended was an evaluation of this set
of systematic reviews in palliative care based on the quan-
tity and quality of primary studies available, and the qual-
ity of the review process itself, in order to determine their
utility for informing clinical practice.
Results
Details of the 25 published systematic reviews [11-35] are
in Additional file 1, together with the conclusions of the
original authors. The first of these Cochrane reviews was
published in 1999, and the most recent in 2007. Sixteen
of the reviews concerned drug interventions for pain or
other reasons, three involved radiotherapy, three comple-
mentary therapy, and one each for a mineral supplement,
supportive care, and pleurodesis. Only five of the studiesPage 2 of 6
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was five per year since 2004.
Primary studies
Number of trials and patients
The numbers of included trials ranged from none to 54.
Thirteen had fewer than five controlled trials, and 16 had
fewer than 10 trials. Three reviews had between 11 and 20
trials, and six more than 20 trials. Six reviews had infor-
mation on fewer than 100 patients in total in controlled
trials, fourteen had fewer than 500, while eight had
between 1000 and 5000, and one more than 6,000
patients (see Additional file 1: Included reviews). Within
each review, included trials were frequently heterogene-
ous, with differing interventions (drug, dose, route, tech-
nique) and reported outcomes, so that the number of
patients contributing to any single analysis was nearly
always much lower than the total number of patients
included in the review.
All the reviews sought randomised controlled trials for
inclusion. Five reviews [22,25,26,30,34] sought uncon-
trolled studies, but only two analysed these in the absence
of randomised trials [22,26]. Two reviews [28,31] found
no studies that met their inclusion criteria.
Types of patients
Eighteen reviews included trials involving only cancer
patients. In most cases the type of cancer or site of the pri-
mary cancer was not restricted. One review included only
AIDS patients [27], two included mixed diagnoses of can-
cer, lung disease, cardiac failure, cystic fibrosis, and elderly
patients [20,33], and one included patients with cancer or
unspecified "terminal illness" [14].
Original authors' assessment of quality of included studies
All reviews with included studies assessed their quality,
with the exception of Ballantyne [22] and Quigley [26],
who found no randomised trials and included mainly ret-
rospective studies, audits, or case reports, and uncon-
trolled prospective cohort studies. A number of scales
were used. Most (18/23) used the Oxford Quality Score
[8], and of these, three [16,29,30] additionally used the
Oxford Pain Validity Scale [36], two [14,21] used Rinck
[1], one [17] used Detsky [37], and another [15] used
both Juni [38] and Delphi [39]. Shaw [24] graded trials
according to criteria in the Cochrane Handbook [40],
Feuer [34] according to Mann [41], and Ezzo et al [18]
used their own set of five questions. Seventeen reviews
also assessed allocation concealment using Cochrane cri-
teria [42] in at least some of the included trials. Eight of
the reviews that assessed trial quality did not use the infor-
mation to exclude low quality studies, weight analyses, or
perform sensitivity analysis for effect of low quality [11-
15,23-25]. For details of quality scores of included studies
see Additional file 2 (Adequacy of included studies), and
of the quality scoring tools used see Additional file 3
(Quality and validity tools).
The original authors themselves indicated that there were
frequently major problems with the primary studies, indi-
vidually or in aggregate. These included low numbers
(either in total or available for pooled analysis) in 18
cases, the lack of useful outcomes in 10, methodological
heterogeneity in eight, design problems in five, and clini-
cal heterogeneity in two. For example, one review stated
that we " ... need more larger studies with standardised
outcomes of clinical relevance and clearer definitions of
best supportive care" [21], while another stated that "Tri-
als were too ...... short term for results to be meaningful"
and that "Clinically relevant questions to address include
which compounds are most beneficial, optimal dose and
administration route, when prophylactic therapy ...
should be started ..." [29].
Reviewers' assessment of quality of reviews
The methods used in these 25 reviews appeared to be
sound. We attempted to use the Oxman & Guyatt Index of
Scientific Quality [7], which asks questions about review
methods. All the reviews had effective search strategies,
and all looked at methodological quality in some way.
However, deficiencies in the primary studies made judg-
ment about assessment of validity and combining data
close to impossible, as it was for the original authors. For
instance, many reviews made no attempt to combine
studies in a pooled analysis because of clinical heteroge-
neity and diverse interventions and outcomes, a decision
that we felt to be correct.
We also felt that an overall Oxman & Guyatt score for
these reviews was inappropriate because it attempts to
measure flaws in the reviewing process. Our judgment
was that the reviewing process was generally good in these
reviews. Limited amounts and quality of data limited con-
clusions about efficacy or harm, most importantly lack of
patient numbers, poor/inconsistent reporting, frequent
use of non-standard outcome measures, and excluding
outcomes which lack clinical relevance, for example
patient satisfaction and long-term morbidity.
In our assessment of the strength of the evidence pre-
sented, we found that of the 25 reviews:
• 2 had no data – there were no trials found [28,31];
• 2 included uncontrolled trials [22,26], known to be the
subject of significant bias [8];
• 12 included randomized trials, but with open or non-
blinded designs [12,14-17,19-21,23-25,35], again known
to be the subject of bias, especially in pain [43];Page 3 of 6
(page number not for citation purposes)
BMC Palliative Care 2008, 7:13 http://www.biomedcentral.com/1472-684X/7/13• 4 included randomized trials, with a mix of blind and
open designs. Of these:
m Wong [32] included mostly double blind studies, with
3600 patients, but using different drugs, doses, and routes
of administration;
m Nicholson [11] had 460 patients and 6/9 trials were
double blind, but with different doses, and routes of
methadone administration, and different comparators;
m Dewey [13] had 60 patients and 4/5 trials were double
blind, but they were insufficiently rigorous to be confi-
dent of any effect;
m Ezzo [18] had 1250 patients in acupuncture trials, with
a mix of techniques and controls. The trials and review
have been criticized elsewhere [44];
• 5 included randomised trials with only double blind
design. Of these:
m Three had fewer than 100 patients [27,30,34];
m Roque [29] had only 325 patients in 4 trials using dif-
ferent drugs, and doses, in single or multiple dose sched-
ules, and for different duration;
m Jennings [33] had 292 patients in 3 trials, but with dif-
ferent drugs and doses.
Two reviews [20,35] were considered to have the strongest
evidence, although even for these reviews there were lim-
itations with methodological heterogeneity or definition
of outcomes. No review provided strong evidence of no
effect. Even reviews with relatively large numbers of trials
and patients could not provide strong evidence because of
inappropriate comparison or trial design [23] or method-
ological heterogeneity [17].
Discussion
This systematic review of systematic reviews in palliative
care was to question the utility of systematic reviews for
informing clinical practice in this area of medicine. It
found that 25 reviews were published in the Cochrane
Database of Systematic Reviews over nine years, a rate of
about 2.7 per year overall, though almost double that rate
occurred in the three years to 2007. Despite a respectable
level of productivity from this prestigious source, 22/25
reviews could produce only weak evidence of the benefits
of any intervention, and even of the two where the evi-
dence was considered to be strong there were caveats.
The review processes themselves appeared adequate. Defi-
ciencies lay in the primary studies, which were either miss-
ing or scant, or were characterized by heterogeneity in the
methods, interventions, patients, and outcomes, which
made an overall assessment of benefit or harm impossi-
ble. These deficiencies are similar to those identified pre-
viously [1-3,5]. The authors of the reviews commonly
commented on these deficiencies, and others. The biggest
single issue was that of inadequate trials or inadequate
patient numbers in high quality trials. In making even this
point, the reviews and the reviewers make an important
contribution.
It is likely that these observations are general to systematic
reviews in palliative care. We limited our investigation to
reviews from the Cochrane Database published through
the auspices of the Palliative Care group, but we would
expect such reviews to be no worse, and perhaps better,
than non-Cochrane reviews [45,46]. The restriction to
Cochrane reviews should not limit any generalisability of
these findings, especially as this reasonably sized body of
reviews consistently makes the same, or very similar,
points.
These findings are not a surprise. The dearth of good
quality primary studies in the field of palliative care is
widely accepted, and those trials that have been done are
often known to have weaknesses [1-3,5]. Together, these
factors underline the limitations of the knowledge base
upon which palliative care has to draw. Whether new
guidance about outcomes to be measured in palliative
care trials would make a difference [4] remains to be
seen, but given the difficulties in design and conduct of
palliative care trials, rapid change in the corpus of evi-
dence is unlikely.
The challenge for palliative care is the lack of evidence that
is available to support it and the inordinate difficulties in
obtaining evidence, for example difficulties with recruit-
ment and attrition in an ill and vulnerable population.
This has led to calls for a different framework for examin-
ing evidence [47]. Part of the problem is that nearly all
randomised controlled trials examine single interven-
tions, while in clinical practice that intervention will often
form a small part of a much larger overall package of care
[5]. Randomised trials of overall packages of care with
small or incremental differences between them are
unlikely to be able to measure small improvements, and
an evaluation of systematic reviews of palliative care serv-
ices [48] highlighted similar problems to those of pallia-
tive care interventions. High patient losses also make
interpretation of randomised trials difficult. It is impor-
tant that palliative care research moves away from
dependence on randomized trials, and explores alterna-
tive study designs to identify the most effective treatments
and packages of care for its patients.Page 4 of 6
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included only randomised trials, and the small number of
reviews that did consider non-randomised studies found
them to have many of the same problems as randomised
trials, with an additional increased risk of bias. We know,
from other areas of medicine, that high quality, well-for-
mulated, and impeccably conducted large observational
studies, can provide equivalent results to those obtained
from randomised controlled trials [6,49,50]. To overcome
the play of chance these good quality studies need to be
large, and to minimise bias they need to be both prospec-
tive and inclusive (i.e. a whole population, or all patients
attending a clinic in a defined time). Registry studies are
studies based on information from registers that systemat-
ically record information from all individuals in a defined
population. They can be entire populations, as in the
death register in the UK, or all patients with a specific
characteristic (eg twins) or condition (eg breast cancer)
within a defined population. At least one large registry-
based programme for continuous quality improvement
aimed at cancer pain is ongoing in Italy [51]. An extensive
search for observational studies in palliative care has been
undertaken, with the aim of identifying good quality
observational studies and aspects of their design that
make them reliable and useful (Hadley et al., manuscript
in preparation). The proven limitation of controlled trials
in palliative care may make registry studies a more accept-
able option in future.
Conclusion
Cochrane reviews in palliative care are well performed,
but fail to provide good evidence to guide clinical practice
because the primary studies are few in number, small,
clinically heterogeneous, and of poor quality and external
validity. These reviews do, however, tell us how limited
the evidence base is, and highlight common deficiencies
in primary studies. There are well-documented problems
with conducting valid randomised trials in this area, and
it may be that for some questions more, and more clini-
cally relevant, information can be obtained from other
types of primary study, such as large registry studies.
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